Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

The Michael J. Fox Foundation Extends Funding for KineMed’s Brain-Process Biomarker Research for PD

Published: Friday, June 29, 2012
Last Updated: Friday, June 29, 2012
Bookmark and Share
KineMed receives $1.2 Million reinvestment from The Michael J. Fox Foundation for the further development of kinetic biomarkers predictive of Parkinson’s disease changes ahead of symptoms.

KineMed, Inc. has announced a further award of $1.2 Million from The Michael J. Fox Foundation towards the ongoing development of kinetic biomarkers that drug developers can use to accelerate and reduce the cost of trials of treatments for Parkinson’s disease (PD).

“The lack of validated biomarkers for Parkinson’s disease is a major hurdle to PD drug development today and so, our Foundation is invested in this critical research,” said Mark Frasier, Ph.D., Vice President, Research Programs for The Michael J. Fox Foundation for Parkinson’s Research.

Frasier continued, “KineMed’s cross-sectional study will look to confirm existing data that we have funded, which has identified biomarkers that are sensitive to subtle changes early in the disease process.”

“We are proud to be extending our work with The Michael J. Fox Foundation and thank the Foundation for this ongoing commitment which recognizes that the development of better biomarkers plays a key role in accelerating progress towards a cure for Parkinson’s disease,” said Dr. Patrizia Fanara, Ph.D., Vice President of Neuroscience, KineMed.

Dr. Fanara continued, “The current difficulty in advancing a cure is the pharmaceutical industry’s challenge to appraise the myriad proposed treatment strategies in concise, cost-effective trials. Our cerebrospinal fluid kinetic biomarkers measure the rate of neurodegeneration in PD patients within weeks, much sooner than any visible effect in disease progression. These fast readouts are stronger and more actionable, so can help companies decide quickly whether or not a drug is working and which patient is responding.”

KineMed’s neuro-biomarker program aims to develop robust, lead indicators of disease progression and regression through identifying and measuring relevant biochemical changes associated with pathology at the cellular level.

These quantitative measures can replace cumbersome symptomatic measures that are sensitive to random fluctuation in the patient’s condition, which are hindering and expanding the cost of trials of CNS drugs in development.

The length and cost of developing a CNS drug is among the highest of any therapeutic area.

A 2011 study by The Tufts Center for the Study of Drug Development reported that an average of 8.1 years was spent in human testing-more than two years longer and more than 50 percent longer in the regulatory approval stage compared with drugs on average.

The study also reported that only 8.2 percent of CNS drug candidates that begin human testing reach the marketplace, compared with 15 percent for drugs overall.

KineMed leads the world in measuring dynamic biochemical processes important in the pathogenesis of the central and peripheral nervous system to identify and verify kinetic marker candidates.

KineMed’s neuro-biomarker platform is unique, in that it reveals the kinetics of molecules through critical processes that drive neuronal dysfunction, disease progression and reparative processes.

These biomarkers thereby predict outcomes and provide key information for disease-modifying drugs in development for neurological disorders.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KineMed, Pfizer Launch Collaboration
KineMed has announced that it has entered into a strategic collaboration with Pfizer to discover and develop novel proprietary biomarkers in various fields of unmet medical need.
Tuesday, January 05, 2016
KineMed and Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies
KineMed’s biomarker platform will allow Amgen to track synthesis and clearance rates of pathogenic proteins in the brain that drive neurodegeneration.
Tuesday, October 15, 2013
Pfizer-KineMed Collaboration Extends to Target Novel Diabetes Pathways
KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Thursday, March 28, 2013
KineMed and CHDI Foundation Collaborate
KineMed’s isotopic labeling technology and analytical expertise will be applied to measure in vivo production rates of huntingtin protein as a potential biomarker of disease state.
Thursday, May 17, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos